Q0139 - Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis) |
1 MG |
0.338 |
- |
- |
- |
- |
- |
- |
|
|
Q0162 - Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
1 MG |
0.013 |
- |
- |
- |
- |
- |
- |
|
|
Q0167 - Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
2.5 MG |
2.417 |
- |
- |
- |
- |
- |
- |
|
|
Q0224 - Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg |
4500 MG |
6583.5 |
95% |
6583.5 |
- |
- |
- |
- |
|
|
Q0249 - Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg |
1 MG |
7.569 |
95% |
7.569 |
- |
- |
- |
- |
|
|
Q2041 - Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
UP TO 200 MILLION CAR T CELLS |
489455.958 |
- |
- |
- |
- |
- |
- |
|
|
Q2042 - Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
up to 600 million CAR-positive viable T cells |
529192.855 |
- |
- |
- |
- |
- |
- |
|
|
Q2043 - Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion |
Per infusion (minimum 50 million cells) |
55015.225 |
- |
- |
- |
- |
- |
- |
|
|
Q2050 - Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg |
10 MG |
133.08 |
- |
- |
- |
- |
- |
- |
|
|
Q2053 - Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CEL |
460530.402 |
- |
- |
- |
- |
- |
- |
|
|
Q2054 - Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
Up to 110 million CAR-positive viable T cells, per therapeutic d |
516726.076 |
- |
- |
- |
- |
- |
- |
|
|
Q2055 - Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
UP TO 510 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CEL |
526587.593 |
- |
- |
- |
- |
- |
- |
|
|
Q2056 - Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
up to 100 million autologous b-cell maturation antigen (bcma) di |
527123.433 |
- |
- |
- |
- |
- |
- |
|
|
Q3027 - Injection, interferon beta-1a, 1 mcg for intramuscular use |
1 MCG |
56.23 |
- |
- |
- |
- |
- |
- |
|
|
Q4074 - Iloprost, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 20 micrograms |
UP TO 20 MCG |
148.334 |
- |
- |
- |
- |
- |
- |
|
|
Q4081 - Injection, epoetin alfa, 100 units (for esrd on dialysis) |
100 UNITS |
0.753 |
- |
- |
- |
- |
- |
- |
|
|
Q4101 - Apligraf, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
30.572 |
- |
- |
- |
- |
- |
- |
|
|
Q4102 - Oasis wound matrix, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
12.252 |
- |
- |
- |
- |
- |
- |
|
|
Q4103 - Oasis burn matrix, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
12.601 |
- |
- |
- |
- |
- |
- |
|
|
Q4104 - Integra bilayer matrix wound dressing (bmwd), per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
50.134 |
- |
- |
- |
- |
- |
- |
|
|
Q4105 - Integra dermal regeneration template (drt) or integra omnigraft dermal regeneration matrix, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
34.679 |
- |
- |
- |
- |
- |
- |
|
|
Q4108 - Integra matrix, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
46.902 |
- |
- |
- |
- |
- |
- |
|
|
Q4110 - Primatrix, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
65.405 |
- |
- |
- |
- |
- |
- |
|
|
Q4111 - Gammagraft, per square centimeter (add-on, list separately in addition to primary procedure) |
1 SQ CM |
7.234 |
- |
- |
- |
- |
- |
- |
|
|
Q4114 - Integra flowable wound matrix, injectable, 1 cc |
1 CC |
1583.766 |
- |
- |
- |
- |
- |
- |
|
|